Tech Company Financing Transactions
Mammoth Biosciences Funding Round
Mammoth Biosciences, based in Brisbane, secured $195 million in investment from Redmile Group, Decheng Capital and Foresite Capital.
Transaction Overview
Company Name
Announced On
9/10/2021
Transaction Type
Venture Equity
Amount
$195,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The funds will enable the company to broaden its toolkit of next-generation CRISPR systems with a focus on building permanent genetic cures through in vivo gene-editing therapeutics and democratizing disease detection with on-demand diagnostics.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1000 Marina Blvd. 600
Brisbane, CA 94005
USA
Brisbane, CA 94005
USA
Phone
Undisclosed
Website
Email Address
Overview
Mammoth's vision is to provide a CRISPR-based platform on which an infinite number of tests can be built by both ourselves and our partners - democratizing access to an endless variety of tests for bio sensing in healthcare, as well as across industries such as agriculture, manufacturing, forensics, and more.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Trevor Martin
Chief Operating Officer
Ted Tisch
Chief Scientific Officer
Lucas Harrington
Chief Technical Officer
Janice Chen
Co-Founder
Jennifer Doudna
VP - Bus. Development
Vikram Joshi
VP - Bus. Development
Peter Nell
Browse more venture capital transactions:
Prev: 9/10/2021: iECURE venture capital transaction
Next: 9/10/2021: Affinity venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. VC transactions on this site are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs